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Summary
Background: There is growing evidence that the
quality of informed consent in clinical research is
often sub-optimal.
Aims: To explore the conformity of patient recruit-
ment with recommended informed consent proced-
ures among patients who were invited to participate
in a clinical study at a general teaching hospital, and
to examine the association between consent proced-
ures and the patients’ decision to participate.
Design and Methods: All inpatients discharged
during a 1-month period were invited to complete
a mailed survey in which they reported whether
they were invited to participate in a study and
whether 13 recommended elements of informed
consent actually occurred.
Results: Among 1303 respondents, 265 (20.3%) re-
ported that they had been invited to participate in a
study, and 191 (72.1%) accepted. While the
majority of potential participants were fully in-
formed about practical issues related to the study
(e.g. what their participation would consist in),
<50% were informed of possible risks or benefits,
and only 20% about the origin of the study funds.
Only 60% reported satisfactory answers to items as-
sessing the overall information process (e.g. explan-
ations were easy to understand). Older and sicker
patients reported lower levels of conformity with in-
formed consent procedures, as did patients who
refused to participate in a study.
Conclusions: Our results confirm that informed con-
sent procedures fail to meet standards for many pa-
tients. In particular, consent information should be
adapted to the needs of older and sicker patients.
Improving the quality of informed consent may in-
crease patients’ participation in clinical research.
Introduction
Patient participation in clinical research is indis-
pensable for the development of evidence-based
medicine. Agreeing to take part in a study is an al-
truistic act1 that may entail certain risks. To protect
research subjects from potential harm2 and to ensure
that they reach an autonomous and informed deci-
sion,3 World Health Organization (WHO) has
adopted an international framework of principles
for informed consent in research (Declaration of
Helsinki4). Based on this framework, regulatory
authorities have further developed official guidelines
such as the ICH guideline for Good Clinical
Practice.5 These recommendations and guidelines
describe information and explanations that investi-
gators are required to provide during the informed
consent discussion and in the written consent
form.4,5 Namely, potential participants should be in-
formed of the purpose and process of the study, their
right to abstain and to withdraw at any time, and of
possible benefits, risks or drawbacks related to their
participation. They should also be informed of the
sources of funding of the study, as of any other
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possible cause of conflict of interest.4 Finally, inves-
tigators should not only disclose information, but
also ensure that participants reach proper under-
standing, particularly by using non-technical and
practical language, adapted to each participant’s
needs and impairments, so that they make an in-
formed and decision.3–5
However, the quality of informed consent in real
life is often sub-optimal, both in terms of conformity
with recommended practices, and in terms of par-
ticipants’ understanding of study-related informa-
tion.6–15 Available evidence in this domain is
fragmented. Most studies to date have assessed the
quality of informed consent in narrow clinical con-
texts, such as oncology,7,8 cardio-vascular medi-
cine9,10 or gynecology.11,12 Furthermore, previous
studies have focused on consent in clinical
trials,13–15 disregarding other types of research.
Another limitation of existing studies is that few
have compared subjects who accepted to partici-
pate and those who refused.16,17 The latter may be
less well-informed about the study, perhaps because
they found consent information hard to understand,
with the potential implication that they may not
have given an informed refusal.6 Further under-
standing of the adequacy of informed consent in
real clinical setting and of its impact on participation
is critical, since most interventions to improve pa-
tient understanding have had only limited suc-
cess,18,19 as have most strategies to improve
recruitment.20
In this study, we examined the conformity of in-
formed consent with recommended procedures
among all potential participants in any clinical re-
search project during their stay at a large public
teaching hospital. Our secondary aims were: (i) to
assess how many inpatients were invited to partici-
pate and whether there was any sub-group that
was more or less likely to be invited; (ii) to examine
the association between adequacy of informed con-
sent and the patients’ decision to participate in the
study.
Methods
Study design and setting
Data were obtained as part of a routine patient opin-
ion survey at Geneva University Hospitals, in
Geneva, Switzerland. This teaching hospital net-
work includes acute care, geriatric, psychiatric and
rehabilitation facilities, totalling 2096 beds and
about 47 000 inpatient admissions annually.
Potential participants were all adult patients hospi-
talized for >24h and discharged either to their
home or to a nursing facility between
15 September and 15 October 2005. The initial
sample was identified through the administrative
database. The survey package was sent by mail to
2469 individuals 4–8 weeks after discharge, with up
to two reminders sent during the next 3 months.
During data collection, we excluded patients who
had moved away, died, stated that they were too
sick to fill in the questionnaire, or did not speak
French. As quality assessment projects that carry
minimal risk, these surveys21,22 are exempted from
full review by the hospital research ethics
committee.
Study variables
The core of the questionnaire was the Picker patient
experience survey.23 This questionnaire includes
mostly questions on various aspects of care received
at the hospital. An example is an item that asks the
patient whether he or she ‘could understand the
doctors’ explanations’, with possible answers ‘yes,
always’, ‘yes, sometimes’ or ‘no’. Only this item
from the Picker survey was analyzed in this article.
Respondents were also asked to report demographic
variables (age, sex, nationality, level of education)
and their perceived general health (item from the
SF-36 questionnaire24,25).
The main variables in this analysis related to pa-
tients’ involvement in clinical research. First, we
asked respondents if they had been invited to par-
ticipate in a study during their hospital stay, and
whether they accepted or refused to participate.
Second, we asked patients who were invited to par-
ticipate in a study to report whether fundamental
aspects of the informed consent process occurred.
We assessed 13 specific aspects of the informed
consent procedure as outlined in the Declaration
of Helsinki4 and in the International Conference
on Harmonization (ICH) Guideline for Good
Clinical Practice.5 We were also inspired by the pre-
vious studies that assessed the quality of informed
consent in specific clinical contexts.10,12,26
Specifically, we asked patients to state whether
they were informed of: the purpose of the study,
what their participation would consist in, possible
benefits, risks or drawbacks, their right to abstain
and to withdraw at any time, and the origin of the
study funds. To assess the information process glo-
bally, we also asked them if they had the opportun-
ity to ask questions, if the explanations as well as
written information were easy to understand, and
finally if they received enough information and
had enough time to decide. As we surveyed poten-
tial participants in studies of various designs, we did
not assess understanding of particular features of
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trials, such as randomization, the unproven nature
of the treatment or the uncertainty of benefits to
themselves.6 To facilitate completion of the ques-
tionnaire we formulated the questions in keeping
with the format of Picker survey items, with possible
answers being: ‘yes, completely – (yes, to some
extent) – no’. One additional item explored the re-
spondents’ overall attitude toward clinical research,
by asking whether it is ‘justified for doctors to ask
patients to contribute to producing knowledge that
will be useful to others’.
Data analysis
We started by comparing respondents who com-
pleted the section exploring involvement in clinical
research to those who skipped the section but filled
out the rest of the questionnaire.
Then, we analyzed the proportion of patients who
reported that they had been invited to participate in
clinical research across sub-groups of respondents.
Among the patients who were invited, we deter-
mined the frequency of conformity with each
aspect of the informed consent process.
To capture the overall conformity with recom-
mendations, we constructed a global conformity
score, as follows:
Conformity score ¼
P 0Yes, completely0  1þ 0Yes, to some extent0  0:5
Number of items
 100
The score was computed among respondents who
answered at least 7 of the 13 relevant items, and
ranged from 0 (lowest possible conformity) to
100 (full conformity on all items). Then, we explored
the overall level of reported conformity across
sub-groups of respondents.
Finally, we analyzed the proportion of patients
who accepted to participate in research according
to the conformity of each aspect of the informed
consent. We built a multiple logistic regression
model to identify aspects that were independently
associated with participation. We used a forward
modeling procedure, guided by the analyst, where
only statistically significant aspects were included in
the model. Data were analyzed using SPSS 15.0
software.
Results
Sample characteristics
During data collection, we excluded 265 patients
from the initial sample because they moved away,
died, did not speak French, of were too sick to re-
spond. Of the 2204 eligible patients, 1432 (65%)
returned completed questionnaires, and 1303
(91% of 1432) filled out the section exploring in-
volvement in clinical research. Respondents to this
section were younger than the 129 non-respondents
(mean age 53 vs. 62 years, P< 0.001), had shorter
hospital stays (mean 9.5 vs. 13.7 days, P=0.017),
had higher level of education (34.1% vs. 14.3%
attended university or a professional school,
P< 0.001), and reported better self-perceived
health status (32.6% vs. 16.9% rated their health
as excellent of very good, P=0.002). Distributions
of others patients’ covariates were similar in the two
groups.
Respondent characteristics are shown in Table 1,
column 1. Few patients from the department of geri-
atrics were included due to an error in the adminis-
trative patient database. Nevertheless, many older
patients were hospitalized in internal medicine,
where 43% of patients were >70 years.
Proportion of patients invited to
participate in clinical research
Among 1303 respondents, 265 (20.3%) reported
that they had been invited to participate in a clinical
research project. Distributions of invited patients
were fairly homogenous across sub-groups of re-
spondents, and no particular group was completely
ignored by investigators (Table 1, column 2).
However, younger patients were more often invited
to participate in research than older patients, and
differences between departments were also statistic-
ally significant.
Conformity with recommended informed
consent procedures
About 75% of the patients invited to participate in a
study reported that they were completely informed
on practical issues, such as the purpose of the study,
the right to withdraw at any time and what their
participation would consist in, and 90% were in-
formed that participation was not obligatory
(Table 2, column 2). However, <50% reported
that they were completely informed of possible
benefits, risks or drawbacks and only 20% reported
that they were informed of the origin of the study
funds. As for the items that addressed the informa-
tion process globally, 60% of the respondents
reported that they had the opportunity to ask ques-
tions, that the explanations were easy to understand
and that they received enough information and
had enough time to decide, and only 50% reported
that written information was completely
understandable.
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The mean conformity score based on all 13 items
was 67.7 (SD=25.9, quartiles = 53.8–73.1–88.4) on
a scale from 0 to 100. It was computed for the
239 (90.2%) patients who reported valid answers
for more than seven conformity items. Three vari-
ables were significantly associated with this score:
age, self-perceived health status and hospital depart-
ment (Table 1, column 3). On average, patients
>65 years reported lower conformity—by about
half a standard deviation—than younger patients,
as did respondents that rated their health as ‘good,
fair or poor’ instead of ‘excellent or very good’.
Informed consent and decision to
participate in a study
Of the 265 patients who were invited to participate
in a research study, 191 (72.1%, or 14.7% of all
respondents) reported that they agreed to partici-
pate, while 53 (20%) refused, and 21 (7.9%) did
not answer this question. Overall conformity with
recommended informed consent procedures was
associated with participation in the study (mean
score 72.6 among those who accepted vs. 51.9
among those who refused, P< 0.001). However,
Table 1 Proportion of patients invited in clinical research and conformity with informed consent procedures across
sub-groups of respondents
Respondents Patients invited to participate
in clinical research
Conformity score of
informed consenta
N b (%) N c Percentage of
respondents
P-value Mean (SD) P-valued
Sex 0.163 0.636
Female 761 (58.5) 165 21.7 68.6 (25.2)
Male 540 (41.5) 100 18.5 66.2 (27.2)
Age (years) 0.014 0.005
18–44 508 (39.0) 124 24.4 71.5 (21.6)
45–64 379 (29.1) 69 18.2 70.7 (27.4)
65 414 (31.8) 72 17.4 57.5 (29.5)
Nationality 0.069 0.836
Swiss 682 (53.0) 145 21.3 69.2 (23.6)
European 403 (31.7) 66 16.4 66.8 (29.0)
Other countries 188 (14.8) 44 23.4 64.9 (27.8)
Level of education 0.071e 0.192
Compulsory school 277 (22.2) 51 18.4 63.2 (28.2)
Apprenticeship 406 (32.6) 73 18.0 66.8 (27.7)
Secondary school 138 (11.1) 29 21.0 69.6 (23.0)
Professional school 185 (14.8) 37 20.0 64.9 (24.0)
University 240 (19.3) 58 24.2 75.0 (20.9)
Length of hospital stay (days) 0.301e 0.306
10 1005 (77.2) 200 19.9 69.4 (24.6)
11–15 230 (17.7) 48 20.9 61.7 (29.9)
>15 66 (5.1) 17 25.8 62.8 (28.8)
Department of hospitalization <0.001 0.034
Medicine 257 (19.8) 62 24.1 67.6 (26.1)
Surgery 452 (34.7) 57 12.6 64.1 (30.8)
Neurosciences 207 (15.9) 30 14.5 58.1 (29.9)
Genecology–obstetrics 294 (22.6) 94 32.0 74.0 (20.7)
Geriatrics 31 (2.4) 9 29.0 51.1 (22.4)
Psychiatry 60 (4.6) 13 21.7 66.4 (24.9)
Perceived health status 0.371 <0.001
Excellent/very good 407 (32.6) 88 21.6 76.5 (21.7)
Good/fair/poor 843 (67.4) 164 19.5 63.2 (26.1)
aScore from 0 to 100 (maximal conformity, see text), mean=67.7, SD=25.9, median = 73.1.
bThe total is different from 1303 because of missing values ranging from 0.2% to 4.4%.
cThe total may be different from 265 because of missing values ranging from 0.0% to 6.4%.
dNon-parametrical test: Mann–Whitney test for comparison of two groups and Kruskal–Wallis test for more than two groups.
eTest for linear trend.
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Table 2 Patient-reported conformity with 13 elements of the informed consent procedure and association with acceptance
to participate in a study
Items of the questionnaire assessing conformity
of informed consent procedure
N a Column
percentage
Row percentage who accepted
to participateb (P-value)
Purpose of the study was explained (<0.001)
Yes, completely 184 75.1 85.9
Yes, to some extent 41 16.7 84.6
No 20 8.2 25.0
Missing, n=20
What your participation would consist in was explained (<0.001)
Yes, completely 180 74.1 87.4
Yes, to some extent 39 16.0 80.0
No 24 9.9 33.3
Missing, n=22
Informed of possible benefits (0.712)
Yes, completely 112 48.3 81.7
Yes, to some extent 43 18.5 78.6
No 77 33.2 76.7
Missing, n=33
Informed of drawbacks and obligations (0.089)
Yes, completely 113 50.0 85.7
Yes, to some extent 43 19.0 70.7
No 70 31.0 77.3
Missing, n=39
Informed of possible risks (0.142)
Yes, completely 110 49.8 83.3
Yes, to some extent 35 15.8 67.6
No 76 34.4 79.5
Missing, n=44
Informed that participation was not obligatory (<0.001)
Yes 219 89.0 85.5
No 27 11.0 26.1
Missing, n=19
Informed of your right to withdraw at any time (0.001)
Yes 174 74.4 85.3
No 60 25.6 64.9
Missing, n=31
Informed of the origin of funding (0.215)
Yes 52 22.4 73.1
No 180 77.6 81.0
Missing, n=33
Had the opportunity to ask questions (0.006)
Yes, completely 136 57.6 85.0
Yes, to some extent 41 17.4 80.5
No 59 25.0 64.3
Missing, n=29
Explanations were easy to understand (<0.001)
Yes, completely 144 62.3 86.6
Yes, to some extent 69 29.9 76.1
No 18 7.8 41.2
Missing, n=34
Written information was easy to understand (0.001)
Yes, completely 118 49.2 89.0
Yes, to some extent 51 21.3 74.5
No or did not receive any written information 71 29.6 66.7
Missing, n=25
Received enough information to decide (<0.001)
Yes, completely 157 65.7 85.4
Yes, to some extent 48 20.1 89.4
No 34 14.2 35.5
Missing, n=26
Had enough time to decide (<0.001)
Yes, completely 148 61.9 88.5
Yes, to some extent 47 19.7 77.8
No 44 18.4 51.2
Missing, n=26
aAmong 265 patients invited to participate, 10 patients showed missing value for this entire section.
bThere were 21 missing answers regarding decision to participate.
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not all items were specifically associated with par-
ticipation (Table 2, column 3). While information on
practical issues was strongly associated with higher
participation rates, information about possible bene-
fits, risks or drawbacks was not. All items assessing
the overall information process were associated with
participation.
To understand if these associations were specific,
we examined study participation in relation to pa-
tient reports of whether doctors’ explanations about
health care (not about research) were completely
understandable, an item from the Picker survey.
This item was not associated with the decision to
participate in research (the proportion of respond-
ents that accepted to participate was of 76.1%
among those who found doctors’ explanation com-
pletely understandable vs. 77.4% among those who
did not).
In multivariate analysis, three items remained sig-
nificantly associated with participation (Table 3),
and accounted for one-third of the variance in par-
ticipation (Nagelkerke R2= 0.32). Unexpectedly,
having received information about the origin of the
study funds had a negative impact on acceptance to
enroll in a study. Further adjustment for the respond-
ent’s general attitude toward research did not
change these results (data not shown).
Discussion
Twenty percent of former inpatients at a public
teaching hospital reported that they had been
invited to participate in clinical research during
their hospital stay, and most of them (72%) agreed
to participate. Although all sub-groups of patients
were approached by investigators, older patients
were less often invited. Potential participants in re-
search did not report a uniformly high level of con-
formity with each of 13 recommended aspects of
informed consent. While information about prac-
tical aspects and the voluntary nature of research
were acceptable, information about risks, benefits
and the origin of funding was poor. As for the efforts
that were made to ensure proper understanding,
only 60% of respondents reported satisfactory an-
swers. Furthermore, the overall conformity with in-
formed consent procedures varied with age and
self-perceived health status, with the older and
sicker patients reporting a less desirable process
than others. Finally, several aspects of informed con-
sent were associated with the actual decision to par-
ticipate, as those who declined participation
reported systematically lower levels of conformity
with informed consent procedures. In multivariate
analysis, information about the purpose of the
study and the right to decline participation were
associated with higher participation rates, while in-
formation about the origin of funding had the oppos-
ite effect.
Proportion of patients invited or
involved in clinical research
About one out of the seven respondents stated that
they participated in a study during their hospital
stay. We were not able to verify the accuracy of
these reports. Our estimate is similar to findings of
a previous study among outpatients of 16 oncology
and cardiology clinics.27 Based on independent
record review, this study found strong evidence of
research participation for 16% (302/1882) of outpa-
tients, and positive and negative predictive values of
patient reports of participation both reached 94%.
An important issue about patient recruitment in
clinical trials is the possible under-representation
of socio-demographic sub-groups such as older
people, women or ethnic minorities.28 We found
no major disparities of this kind. However, like
others, we found that older patient were less likely
Table 3 Independent predictors of participation in clinical research
Adjusted OR (P-value) 95% CI
Purpose of the study was explained (0.001)
Yes, completely 10.41 (2.77–39.16)
Yes, to some extent 10.44 (2.25–48.45)
No Reference –
Informed that participation was not obligatory (<0.001)
Yes 10.39 (3.18–40.00)
No Reference –
Informed of the origin of funding (0.005)
Yes 0.29 (0.12–0.69)
No Reference –
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to report being recruited.29 This could be a true find-
ing, or an example of information bias, as older pa-
tients may lack a clear understanding of whether
they were enrolled in research.30
Conformity with recommendations on
informed consent
Our findings about practical information, such as
the purpose of the study and the voluntary nature
of research, are similar to those of previous studies
of specific trials.7,13,31 However, our patients re-
ported a less-satisfactory information process than
others. For example, in a study of 207 patients
with cancer who were recently enrolled in a clinical
trial, 93% reported that they had had sufficient op-
portunity to ask questions, 86% reported that the
consent form was easy to understand and 87%
said they had enough time to learn about the
trial.7 In contrast, only 50–60% of our respondents
reported similar answers to these items.
The patients we surveyed were invited to partici-
pate in various types of studies, not just randomized
trials, and were likely older or more severely ill than
outpatients recently enrolled in specific clinical
trials.7,13,27,31,32 Older and sicker patient report
lower levels of adequacy of the informed consent
procedure, as we and others30,31 have observed.
One possibility is that older and sicker patients
were enrolled in studies that had less appropriate
practices in place. Alternatively, such patients may
suffer from discrimination, independently of the
nature of the study. For instance, study information
may be tailored to younger and healthier people.
These results emphasize the importance of adapting
consent information to patients’ needs and impair-
ments, especially to more vulnerable sub-groups of
patients, so that they can also make an informed
decision.
Adequacy of informed consent and
decision to participate
In contrast with most previous work, we obtained
information from patients who refused to participate
in research. Those who refused reported significant-
ly lower levels of conformity with informed consent
procedures. This raises a red flag, as these potential
participants may not have given an informed refusal.
Alternatively, those who declined participation may
remember less well the recruitment process than
those who agreed to participate. However, we be-
lieve that information bias is an unlikely explan-
ation, given the strength and the specificity of the
observed associations.
Indeed, not all aspects of the conformity with rec-
ommendations were associated with participation.
For instance, the decision to participate was only
marginally affected by information about possible
risks or drawbacks. This is reassuring, since these
aspects of a study are often emphasized in patient
information documents.3
Another interesting finding is the negative impact
of financial disclosure on participation in multivari-
ate analysis. This association was not observed in
univariate analysis, probably because it was con-
founded by the positive association between overall
conformity on the other items and the decision to
participate. Indeed, patients who reported that they
were informed of study funds also reported higher
levels of overall conformity on the other items (85.0
vs. 66.2, P< 0.001), which probably masked the
negative impact of financial disclosure.
Investigators are expected to disclose any poten-
tial conflict of interest, including sources of fund-
ing,4 in order to fully inform research subjects and
strengthen the trust relationship between the public
and the scientific community.33 However, there is
controversy about the impact of such disclosure on
recruitment. Others have found that financial dis-
closure is unlikely to affect the decision to partici-
pate in a hypothetical trial.34 Information about the
origin of funding may reduce participation in clinic-
al settings, if patients generally considered only al-
truistic motives of researchers and were unaware of
commercial implications. On the other hand, finan-
cial disclosure may have occurred more often in
situations that investigators considered as possibly
problematic (e.g. funding by private industry),35
hence the negative impact on patient participation.
Both explanations raise the ethical problem of
weighing recruitment considerations and the duty
to fully inform potential participants.
Limitation and strengths
The main limitation of the study is the lack of inde-
pendent verification of patients’ reports. To protect
the privacy of respondents in the satisfaction survey,
we did not have access to their medical records.
However, previous studies27 suggest that the pa-
tients’ recall of research is generally good. As for
any study based on self-reports, social desirability
bias and recall bias may also apply to our results.
The moderate response rate raises the possibility
of selection bias. This would probably inflate re-
ported levels of conformity, as respondents to the
research section of the survey tented to be younger,
more educated and in better health. However, an
analysis of a similar survey at the same hospital
showed that non-response bias was modest, at
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least for the Picker patient opinion survey.22 On bal-
ance, as discussed above, we believe our results are
internally valid. However, only one hospital was
involved, so that the generalizability of our findings
is questionable.
The main strengths of our study are that we tested
a wide array of recommended elements for informed
consent, and that we included both patients who
accepted and who refused to participate in clinical
research, in contrast with previous studies. We were
thus able to explore how adequacy of informed con-
sent may influence patients’ decision to participate.
However, we did not consider other important fac-
tors that may impact on their acceptance, such as
attitudes toward clinical research, perceived risks
and expected benefits of their participation or the
burden it may entail.36,37 Indeed, conformity with
informed consent procedure explained only
one-third of the variance in participation in our
multivariate analysis.
Finally, we surveyed a large unselected sample of
potential participants, in contrast, with previous re-
search that assessed the quality of informed consent
in narrow clinical contexts and focused on consent
in clinical trials. Thus our study may yield a wider
assessment of conformity with informed consent
procedures in real clinical settings. At the same
time, this is also a limitation, since our sample is
heterogeneous and we were not able to relate
patients’ reports to actual informed consent
documents.
Conclusion
Our results confirm that the informed consent pro-
cess for research studies is imperfect, particularly
regarding information on risks or financial disclos-
ure. Our results also call attention to the need to
adapt consent information to vulnerable sub-groups
of patients. Improvement of informed consent may
contribute to increase participation in research,
since non-participants reported a lower quality of
the consent process, in addition to enabling poten-
tial participants to reach an informed decision.
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